bluuebunny/crossref_metadata_2025_split huggingface dataset:
Toward work’s new futures: Editors’ Introduction to Technology and the Future of Work special issue
Authors: Baym Nancy , Ellison Nicole B 
Published: June 2023

Abstract
This special issue is based in the belief that theoretically informed, methodologically diverse, and sociotechnically inspired research is our best approach for understanding contemporary entanglements between the technological and social aspects of work, and for grappling with what that means for our futures. In this Editors’ Introduction to JCMC’s Technology and the Future of Work special issue, we synthesize emergent themes across the eleven papers included and reflect on productive analytic lenses for anticipating how technologies may shape social and work practices, and vice versa. We identify four themes woven across the papers—visibility, relationships, boundaries, and power—and explicate some of the ways that social, technical, temporal, and communicative dimensions of work emerge across a variety of work contexts. Together, these papers highlight the creative, sense-making, and collaborative dynamics of the technologically infused workplace while acknowledging the amorphous nature of work and place, past, present and future.
Hansen Lecture 2022: The Evolution of the Use of Models in Survey Sampling
Authors: Valliant Richard 
Published: June 2023

AbstractMorris Hansen made seminal contributions to the early development of sampling theory, including convincing government survey administrators to use probability sampling as opposed to nonprobability (NP) methods like quota sampling. He codified many of the early results in design-based sampling theory in his 1953 two-volume set co-authored with Hurwitz and Madow. Since those developments, the explicit use of models has proliferated in sampling for use in basic point estimation, nonresponse and noncoverage adjustment, imputation, and a variety of other areas. This paper summarizes some of the early developments, controversies in the design-based versus model-based debate, and uses of models for inference from probability and NP samples.
(007) Physical activity and female sexual dysfunction: too much of a good thing?
Authors: Maseroli E , Rastrelli G , Di Stasi V , Cipriani S , Scavello I , Todisco T 
Published: June 2023

Abstract

Introduction
Research on the relationship between physical activity (PA) and female sexual dysfunction (FSD) is lacking.

Objectives
To investigate the clinical, psychological, and sexual correlates of PA in women with FSD.

Methods
A non-selected series of n=322 pre- and post-menopausal patients consulting for FSD was retrospectively studied. Regular involvement in PA and its frequency (&lt;1 hour/week: sedentary, 1-3 hours/week: active, 4-6 hours/week: very active, &gt;6 hours/week: extremely active) were investigated with a specific question. FSDs, including HSDD (Hypoactive sexual desire disorder) and FGAD (Female genital arousal disorder), were diagnosed according to a structured and clinical interview. Participants underwent a physical examination and a clitoral Doppler ultrasound, and were asked to complete the Female Sexual Function Index (FSFI), Female Sexual Distress Scale-Revised (FSDS-R), Body Uneasiness Test (BUT), and Middlesex Hospital Questionnaire (MHQ).

Results
At multivariate analysis, women engaging in PA (67.4%, n=217) scored significantly higher in several FSFI domains - including desire, arousal and lubrication - and showed lower sexual distress and lower resistance of clitoral arteries, as compared to sedentary women. A significant, inverse association between PA and HSDD was observed. Mediation analysis demonstrated that the negative association between PA and HSDD was partly mediated by body image concerns (BUT Global severity index), psychopathological symptoms (MHQ total score) and sexual distress (FSDS-R score). These latter two factors also partly mediated the association between PA and a reduced risk of FGAD, whilst a lower BMI was a full mediator in the relationship between PA and FGAD. Finally, extreme PA was associated with significantly worse scores in several psychosexual parameters (i.e. sexual satisfaction and histrionic/hysterical symptoms), even compared to a sedentary lifestyle.

Conclusions
In women with FSD, PA was associated with better sexual function and clitoral vascularization, lower sexual distress and reduced odds of HSDD and FGAD; the benefits of PA on sexuality were mediated by both psychological and organic determinants; excessive PA was related with a poor overall sexual function and with a low sexual satisfaction.

Disclosure
No.
(008) Chronic High Fat Diet Decreases Vaginal Smooth Muscle Tone but does not Affect Pelvic Floor Skeletal Muscle in Mice
Authors: Burleson L , Odom M , Amorese A , Spangenburg E , Hannan J 
Published: June 2023

Abstract

Introduction
Pelvic organ prolapse (POP) is a disease that affects the physical and mental health of women, as well as their quality of life. POP, regardless of severity, can be a direct cause of female sexual dysfunction (FSD) by producing pain during intercourse or a general reluctance to engage in sexual activity. The largest risk factors for POP include parity, obesity, and advanced age. Obesity, a modifiable risk factor, is believed to increase intra-abdominal pressure and weaken the pelvic floor muscles and fascia. Studies have shown that obesity and a high fat diet (HFD) can weaken skeletal muscle by increasing collagen deposition and inducing muscle apoptosis.

Objectives
There is paucity in the literature of animal studies that have specifically investigated the effect of obesity on the support structures of the pelvic floor and how it contributes to POP. The objective of this study is to examine the structure and function of the vagina and pelvic floor in female mice fed a chronic HFD.

Methods
Adult female C57/Blk6N mice (10 weeks, n=32) were fed a control (10% kcal fat) or HFD (45% kcal fat) for 24 weeks. Ex vivo external vaginal sphincter contraction to increasing concentrations of adrenergic agonist norepinephrine and relaxation to nitric oxide donor DEA NONOate and electric field stimulation (EFS) was measured. Iliococcygeus (IC) muscles of the pelvic floor were isolated and set to optimal length and tetanic contractions were performed at increasing frequencies to asses absolute and specific force. Fatigue was measured following repetitive stimulations over 5 minutes. IC muscle fiber types were characterized with anti-myosin antibodies and cross-sectional area (CSA) of each fiber type was measured.

Results
Vaginal sphincter adrenergic-mediated contraction was a significantly decreased in HFD-fed mice (Fig 1A; p&lt;0.05). The vaginal sphincter smooth muscle relaxation in response to a nitric oxide donor was greater in the HFD mice (Fig 1B; p&lt;0.05). Neurogenic-mediated EFS vaginal relaxations were also enhanced in the HFD mice (p&lt;0.05). Surprisingly, chronic HFD did not impact iliococcygeus muscle specific force, absolute force, or muscle fatigue (Fig 1C). Furthermore, HFD did not affect the CSA or population of type I, IIa, IIX, or IIb iliococcygeus muscle fibers.

Conclusions
HFD-induced obesity in mice leads to pelvic floor weakness by enhancing relaxation and decreasing tone of the vaginal smooth muscle. Interestingly, the function and composition of pelvic skeletal muscle was unaffected by HFD. As the vagina serves as a primary support structure to the pelvic organs, lack in muscle contractility and increase in relaxation following HFD suggests that obesity-induced POP may play a direct role in FSD.

Disclosure
(015) STOMP: Sexual function Trial of Overactive bladder: Medication versus PTNS
Authors: Polland A , Hamner J , Arunachalam D , Dwarica D , Gupta A , Pennycuff J 
Published: June 2023

Abstract

Introduction
Female sexual dysfunction affects approximately 45% of women, and an even greater percentage of those with overactive bladder (OAB). Sexual function, measured by the Female Sexual Function Index (FSFI), has been shown to improve with treatment of OAB. To date, no study has compared the effects of percutaneous tibial nerve stimulation (PTNS) versus medication (anticholinergics (ACH) or beta-agonists (BAG)) on sexual function.

Objectives
The objective of this study was to compare the effect of PTNS and medical therapy (MT) with ACH or BAG on female sexual function.

Methods
This was a prospective multi-center cohort study. Sample sizes of 63 per group were calculated to be necessary to detect a clinically relevant difference in the primary end point, FSFI. Sexually-active women with OAB completed the Overactive Bladder questionnaire (OAB-q), FSFI, Beck Depression Inventory and a visual analog pain scale prior to and after 12 weeks of therapy.

Results
175 patients were recruited and 104 completed follow up (58/108 ACH, 31/49 BAG, 13/18 PTNS). The PTNS group had lower overall FSFI (p=0.04), worse pain (p=0.01) and decreased lubrication (p=0.006) compared to the BAG and ACH groups. After treatment there were no significant differences between the groups in overall or sub-domain FSFI scores. There were within-group FSFI differences from pre- to post-treatment, with a worsening of arousal in the ACH group (p=0.046) and an improvement in overall FSFI (p=0.04) and pain (p=0.04) with BAG. After treatment, postmenopausal women in the BAG group had significantly better overall FSFI (p=0.01), desire (p=0.003), arousal (p=0.009) and orgasm (p=0.01).

Conclusions
While both PTNS and MT improved OAB, ACH resulted in worsening of aspects of sexual function, such as arousal, while BAG improved overall sexual function and pain. Improvement in sexual function with treatment was pronounced in the sub-group of postmenopausal women. While further research in necessary, this study provides additional information about the comparative effects of OAB treatments on female sexual function, which may ultimately lead to better patient selection and outcomes.

Disclosure
No.
(016) The Effect of Phosphodiesterase-5-inhibitor on Female Sexual Function: A Systematic Review and Meta-analysis
Authors: Khashaba S , Bruce A , Krishan A , Ehsanullah S , Ndrika S , Khela A 
Published: June 2023

Abstract

Introduction
The link between the attainment of healthy sexual function and a high quality of life in women is well established. However, while the management of male sexual dysfunction has been afforded huge research and development, far less time and effort has been lent in the achievement of successful remedies for females experiencing sexual dysfunction. The use of oral phosphodiesterase type 5 (PDE5) inhibitors, such as Sildenafil, has been the mainstay of treatment for male sexual dysfunction for the last two decades. PDE5 inhibitors have been shown to initiate penile erection, through smooth muscle relaxation and the subsequent increase in intracellular cGMP levels. PDE5-containing cells, similar to those found in the penis, have also been confirmed within the clitoris. No previous pooled analysis has been performed, looking at the possible effect of PDE5 inhibitors on female sexual function, in a population comprising of heterosexual cisgender population.

Objectives
We aimed to perform a systematic review and meta-analysis of the best possible available studies, to evaluate the efficacy and safety of PDE5 inhibitors versus placebo when used in an exclusively female population.

Methods
We conducted a comprehensive search of electronic databases (MEDLINE, PubMed, EMBASE, CINAHL, CENTRAL, SCOPUS, Google Scholar, Web of Science, EBSCO Host, TRIP and Epistemonikos), identifying studies comparing the PDE5 inhibitors versus placebo, and the resultant effect on female sexual function. The Cochrane risk-of-bias tool for RCTs and the Newcastle-Ottawa scale for observational studies were used to assess the included studies. Random effects modelling was used to calculate pooled outcome data.

Results
Searches of electronic databases resulted in 67 articles, from which 13 randomised control trials (RCTs) met the eligibility criteria, enrolling a total of 1605 patients. The use of PDE5 inhibitor was associated with a significantly improved orgasm satisfaction (P=0.01), increased sexual arousal (P=0.02), increase in sexual satisfaction (P=0.007) when compared to placebo. The use of PDE5i was also found to have a significant association with the incidence of headaches (P&lt;0.0001) and flushing (P&lt;0.00001).

Conclusions
Our meta-analysis demonstrated that the use PDE5 inhibitor was associated with a significantly higher attainment of orgasm satisfaction, sexual arousal, and sexual satisfaction when administered to a solely female population, when compared with placebo. However, the use of PDE5 inhibitors was also associated with a significantly increased risk of headache and flushing. Further large-scale high-quality RCTs are required in order to further evaluate the potential role of PDE5i’s in women, particularly in those suffering from significant sexual dysfunction. These future studies should focus on a more homogenous patient group, with stricter definitions of inclusion criteria.

Disclosure
(024) Sexual, Psychological, Interpersonal Well-being and (Unmet) Supportive Care Needs of Couples After a Gynaecological Cancer Treatment
Authors: Dalex P , Aerts L 
Published: June 2023

Abstract

Introduction
Previous research has shown that gynecological cancer negatively affects the psychological and sexual well-being of patients. However, little is known on the impact of a gynecological cancer on the partner’s sexual, psychological and social function and on the supportive care needs of couples during and after the cancer treatment.

Objectives
To assess the sexual, psychological and relational functioning of women and their partners after a gynecological cancer treatment and to assess their (unmet) supportive care needs during and after treatment.

Methods
Patients treated for a gynecological cancer at the [blinded for review] between January 2012 and September 2019 and their partners completed self- reported questionnaires. Participants completed the Spielberger State-Trait Anxiety Inventory, the Beck Depression Inventory II, the Female Sexual Function Inventory, the International Index of Erectile Function’s, the Sexual Distress Scale’s, the Couple Satisfaction Index’s, and the Dyadic Sexual Communication Scale. In addition, they completed a self-reported questionnaire on (unmet) supportive care needs during and after treatment.

Results
Sixteen couples participated in the study. Mean age was 59.5 (range 46-72) for women and 63 (range 50-76) for men. The mean duration since treatment was 3 years (range = 1-7).Thirty-eight percent of women and 23% of men reported moderate to high levels of anxiety whereas 18,75% of women and no men suffered from moderate to severe depression. Sixty percent of patients reported a sexual dysfunction and 40% reported significant sexual distress. Eighteen percent of men reported an erectile dysfunction and 33% reported a significant sexual distress. Whereas most couples were satisfied about their relationship, difficulties in sexual communication were expressed by most couples. Receiving psychological support, information and help with the changes in the sexual life were the most widely supported care needs of patients and partners during and after treatment. Although the highest domains of unmet needs during and after treatment for both partners were in the informational, relational and physical domain, more than 50% of couples reported unmet needs in the sexual domain.

Conclusions
Gynecological cancer and treatment negatively affects the psychological and sexual well-being of both the patient and her partner. Support during and after treatment should take aspects such as psychological and sexual distress and the partner perspective into account.

Disclosure
No.
(033) Exploring the Link Between Autoimmune Disorders and Painful Sex in Ova-Having Bodies
Authors: Washington K , Wyatt H 
Published: June 2023

Abstract

Introduction
Sexual pain in females is an increasingly relevant issue, presenting frequently in offices of couple and sex therapists alike. A study of 3,000 Americans ages 18 to 59 found that sexual dysfunction was more prevalent for women (43%) than men of the same age group (31%), and that the marker of poor health in females was directly related to sexual pain specifically (Laumann et al., 1999). A multitude of studies show a circular relationship amongst immune function, inflammation, and sexual activity. This circular relationship sometimes becomes a feedback loop from which sexual pain occurs (Lorenz et al., 2015). Additionally, an important overlap between research in autoimmunity and research around inflammation and sexual pain is the presence of adverse childhood experiences (ACE’s), identification of low socioeconomic status, and education status (Basson, 2012; Khandker, 2011), making this problem potentially relevant to the entire family system.

Objectives
1: To attain understanding of psychoneuroimmunology, autoimmunity, and pain with sex as separate key factors. 2: To begin tracing the bidirectional influences of mind-body interactions on both expression of autoimmunity and on pain with sex in ova-having bodies. 3: To conceptualize the proposed comorbidity of autoimmunity and pain with sex in ova-having bodies and why it is important to systemic therapists.

Methods
The presenters examine and review existing data and literature from the fields of psychology, medicine, psychoneuroimmunology, and sex therapy.

Results
Current research supports a connection between chronic stress and its effect on the immune system, and chronic stress’ effect on those possessing ovarian reproductive systems during sexual activity. The presenters noticed a tendency of comorbid diagnosis of autoimmune disease in many ova-having individuals who present to therapy with the experience of pain during sexual intercourse.

Conclusions
Given that autoimmune disorders and pain with sex are prominent issues in ova-having persons, this literature provides a new option in clinical considerations when a client with the comorbid diagnosis of autoimmune disorder and sexual pain comes in for treatment. Knowing that an overlap in diagnosis exists, this research informs and encourages clinicians to investigate the comorbidity of pain with sex if autoimmune disorder is present and vice versa. Therapists can better assist with the emotional and cognitive aspects of autoimmune disorders and pain with sex. Both diagnoses are correlated to anxiety, depression, perfectionism, and high/chronic stress levels. Whether to help heal preventively or to aid the client in emotions and stress after the diagnosis has been made, the therapist is key to aiding the client’s cognitive and emotional aspects of diagnosis.

Disclosure
No.
(057) Retrospective Cohort Study: Associations Between Gynecology Provider Level and Female Sexual Dysfunction Screening Rates during Annual Exams
Authors: Berry W , Capbarat E , Rosenberg S , Walker T , Keegan E , Carter-Brooks C 
Published: June 2023

Abstract

Introduction
Female sexual dysfunction (FSD) is a broad term that encompasses personal distress from various aspects of intercourse including desire, arousal, orgasm, or pain. Various studies report a high prevalence of 10-20% in women, FSD screening rates are low in the United States.

Objectives
The objectives of this study are to determine if provider type or provider level of training affect rate of FSD screening at annual well-woman visits, and to compare rates of FSD screening compared to other screening including depression, cervical cancer, and breast cancer.

Methods
We performed a retrospective cohort study chart review of patients from our outpatient gynecology office who underwent a well-woman annual visit. Women were eligible if at least 18 years of age, new patients, sexually active now or in the past, were seen by a provider in our gynecology department (attending, resident, midwife, or nurse practitioner), and used English as a primary language. Charts were identified within the gynecology department between 11/1/2017 and 1/31/2020 by looking up visits with CPT codes 99385, 99386, and 99387, as well as GC modifiers to identify resident-level providers. The attending-level physician, nurse practitioner, and certified nursing midwife visits were matched to resident-level visits by CPT code and similar date of service. The primary outcome is comparative rates of FSD screening by resident-level providers versus attending-level providers. Secondary outcomes including comparative rates of FSD screening amongst other provider types, and comparison of FSD screening versus depression, cervical cancer, and breast cancer screening. Outcomes will be analyzed using Chi-square testing (if more than 5 patients are screened for FSD from each provider-type) or Fisher’s exact test (if no more than 5 patients are screened for FSD from any provider-type). Multivariable logistic regression modeling will be used to identified any associations between patient or provider demographics that may affect screening rates (patient age, race, insurance type, sex of provider, etc.)

Results
We have approximately 400 total charts identified for review, which is ongoing and approximately 20% complete. We anticipate reporting results and conclusions after completion of chart review.

Conclusions
We have approximately 400 total charts identified for review, which is ongoing and approximately 20% complete. We anticipate reporting results and conclusions after completion of chart review.

Disclosure
No.